At a small mountain ranch in Sweetwater, Colo., University of Colorado Cancer Center patients are...
Paul A. Bunn, Jr, MD earns 2014 “Giants of Cancer Care” award
June 11, 2014 · Comments Off
AURORA, Colo. – University of Colorado Cancer Center investigator Paul A. Bunn, Jr, MD, has...
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
One Step Closer to a Breath Test for Lung Cancer
May 31, 2014 · Comments Off
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
ALK, ROS1 and now NTRK1: Study Shows Prevalence of New Genetic Driver in Lung Cancer
May 31, 2014 · Comments Off
Study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other work from Dr. Doebele’s group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid tumors (NCT02122913).
AURORA, Colo -The Journal of Clinical Oncology reports the case of a woman diagnosed with...
Lung and bladder cancers have common cell-cycle biomarkers
January 29, 2014 · Comments Off
CU Cancer Center study: bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle.
CU Cancer Center study shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rate compared with patients forced to discontinue the drug sooner.
Hospital Carries the Fight to Lung Cancer, Denver Market
January 9, 2014 · Comments Off
Perhaps you’ve seen the images. University of Colorado Hospital’s recently launched advertising campaign centers on...
NTRK1: a new oncogene and target in lung cancer
January 9, 2014
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
We're thankful for small cancer foundations willing to fund early detection cancer research. Thank you Whedon... fb.me/6I2ctMQH2
Have you bought your tickets yet? Dinner in White is less than one month away! This is one of Denver's premiere... fb.me/6LH0jyxP0
“Organizations like Epic Experience allow cancer fighters and survivors to escape the stress of your “cancer... fb.me/2pYw5GfiE
Mallets for Melanoma is this weekend! You will not want to miss out on this unique event! fb.me/3EC04KOgx
"I’m hoping to be able to breathe better and live a little bit longer to be a mom to my baby girl." Tabitha... fb.me/2feb9fMGv